Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives $17.20 Average Price Target from Analysts

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has been assigned an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $17.20.

Several research analysts have recently weighed in on the company. Wall Street Zen upgraded Senseonics Holdings, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. Mizuho cut their target price on shares of Senseonics Holdings, Inc. Common Stock from $20.00 to $18.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Weiss Ratings cut Senseonics Holdings, Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 12th.

Insider Activity

In related news, Director Douglas Roeder bought 13,953 shares of the stock in a transaction dated Wednesday, August 19th. The shares were purchased at an average price of $8.98 per share, with a total value of $125,297.94. Following the completion of the acquisition, the director owned 171,191 shares of the company’s stock, valued at $1,537,295.18. This represents a 8.87% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Integrated Wealth Concepts LLC purchased a new stake in shares of Senseonics Holdings, Inc. Common Stock in the second quarter valued at $36,000. Ausdal Financial Partners Inc. lifted its stake in Senseonics Holdings, Inc. Common Stock by 50.0% in the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares during the last quarter. GSK plc purchased a new position in shares of Senseonics Holdings, Inc. Common Stock during the fourth quarter valued at approximately $60,000. The Manufacturers Life Insurance Company purchased a new position in shares of Senseonics Holdings, Inc. Common Stock during the second quarter valued at approximately $65,000. Finally, State of Wyoming bought a new position in shares of Senseonics Holdings, Inc. Common Stock during the second quarter valued at approximately $67,000. 12.36% of the stock is currently owned by institutional investors.

Senseonics Holdings, Inc. Common Stock Stock Performance

Senseonics Holdings, Inc. Common Stock stock opened at $8.71 on Friday. The company has a current ratio of 6.74, a quick ratio of 6.40 and a debt-to-equity ratio of 0.62. The firm has a market cap of $364.08 million, a P/E ratio of -3.91 and a beta of 1.08. Senseonics Holdings, Inc. Common Stock has a 1-year low of $4.79 and a 1-year high of $11.58. The firm has a 50-day moving average of $7.08 and a 200-day moving average of $6.71.

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.08). Senseonics Holdings, Inc. Common Stock had a negative net margin of 225.09% and a negative return on equity of 165.80%. The firm had revenue of $14.48 million for the quarter. Sell-side analysts expect that Senseonics Holdings, Inc. Common Stock will post -2.29 EPS for the current year.

Senseonics Holdings, Inc. Common Stock Company Profile

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.